Xiao Chen1,2, Sumei He3, Dongdong Wang2. 1. Department of Pharmacy, The People's Hospital of Jiangyin , Jiangyin, China. 2. Department of Pharmacy, Children's Hospital of Fudan University , Shanghai, China. 3. Department of Pharmacy, The Affiliated Suzhou Science & Technology Town Hospital of Nanjing Medical University , Suzhou, Jiangsu, China.
Abstract
OBJECTIVES: The present study aimed to investigate the effects of metformin on body weight in polycystic ovary syndrome (PCOS) patients by model-based meta-analysis (MBMA). METHODS: Randomized controlled trial (RCT) studies of metformin in treatment of PCOS patients were collected and efficacy indicators were the body mass index (BMI) change rates from baseline. RESULTS: 28 RCT studies, 1631 PCOS patients were included for analysis. Model of metformin monotherapy, and model of metformin combination therapy were established, respectively. After deducting control group effects, the Emax of metformin on BMI were -5.88% and -11.8% in metformin monotherapy and metformin combination therapy, respectively. In order to play better curative effects, for metformin monotherapy, 1000 mg/day metformin needs for at least 25.5 weeks; For metformin combination therapy, 1000 mg/day metformin needs for at least 58.6 weeks. CONCLUSION: It was the first time to quantify the effects of metformin on body weight and recommend dose and duration for metformin monotherapy and metformin combination therapy in PCOS patients.
OBJECTIVES: The present study aimed to investigate the effects of metformin on body weight in polycystic ovary syndrome (PCOS) patients by model-based meta-analysis (MBMA). METHODS: Randomized controlled trial (RCT) studies of metformin in treatment of PCOSpatients were collected and efficacy indicators were the body mass index (BMI) change rates from baseline. RESULTS: 28 RCT studies, 1631 PCOSpatients were included for analysis. Model of metformin monotherapy, and model of metformin combination therapy were established, respectively. After deducting control group effects, the Emax of metformin on BMI were -5.88% and -11.8% in metformin monotherapy and metformin combination therapy, respectively. In order to play better curative effects, for metformin monotherapy, 1000 mg/day metformin needs for at least 25.5 weeks; For metformin combination therapy, 1000 mg/day metformin needs for at least 58.6 weeks. CONCLUSION: It was the first time to quantify the effects of metformin on body weight and recommend dose and duration for metformin monotherapy and metformin combination therapy in PCOSpatients.
Entities:
Keywords:
Metformin; body weight; model-based meta-analysis; polycystic ovary syndrome